According to the latest research published by Future Market Insights, the global enzyme replacement therapy market is poised to expand at 6.5% compound annual growth rate (CAGR) over the 2018–2028 forecast period.

The global market for enzyme replacement therapy is expected to exceed $13.78m by the end of 2028, attesting for the high growth rate in Japan, which is expected to expand at 12.5% CAGR over the 2018–2028 forecast period.

Increasing per-capita healthcare expenditure in North America is expected to push market revenue growth. The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populous regions of the Asia Pacific (APAC) and China are expected to play an important role in driving revenue growth of the global enzyme replacement therapy market.

Global enzyme replacement therapy market segmentation and forecast

The global enzyme replacement therapy market has been segmented on the basis of therapeutic condition, route of administration, distribution channel and region.

Therapeutic conditions in the enzyme replacement therapy market include Fabry disease, Gaucher disease, mucopolysaccharidosis, Pompe disease, and lysosomal acid lipase deficiency. Globally, the mucopolysaccharidosis therapeutic condition is the most attractive segment, while the injectable segment remains the most lucrative route of administration in the enzyme replacement therapy market.

Among all distribution channels for enzyme replacement therapy, speciality treatment pharmacies are expected to be the most lucrative, followed by hospital pharmacies.

Global enzyme replacement therapy market regional insights

With nearly 30% market share, North America dominated the global enzyme replacement therapy market in 2017, partly due to the presence of leading market players in the region.

In developing regions such as Latin America, advancements in medical facilities are helping the region cope with a healthcare crisis. Medical facilities in Brazil are equivalent to hospitals in the US, with some even exceeding US standards.

Brazil offers everything from large, full-service hospitals to smaller, intimate private clinics. Brazil has developed into a centre of excellence for healthcare in Latin America, with major universities that support research, teaching and training of medical professionals.

Western Europe is the second largest market globally and is expected to be valued at $2.89m by 2028, with France, Italy and Spain projected to witness significant growth rates. Japan is expected to be the third largest market for enzyme replacement therapy.

The key research findings include:

• Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create an incremental opportunity of $6.45m between 2018 and 2028
• When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing government support and growing demand for enzyme replacement therapy for the treatment of rare diseases

Global enzyme replacement therapy market competitive landscape

The global market is highly consolidated owing to the presence of several players. Some of the key players are Sanofi (Genzyme Corporation), Shire, Pfizer, Alexion Pharmaceuticals, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Johnson & Johnson Services, Allergan, and Leadiant Biosciences.

Companies in the global enzyme replacement market are focusing on strategic initiatives such as alliances and agreements, collaborations, increasing research and development (R&D) activities, new product launches, joint ventures (JV), partnerships, and mergers and acquisitions to sustain in the competitive global market.

To request a sample report, click here.

To read a comprehensive overview with a TOC, click here.